stockrow
Saturday 7 November 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
- EPS
- +63.3%
- Free cash flow
- −50.1%
Quarter to June 2026, against a year earlier
3.90
0.13
+3.45%
Follow RLMD
Alert me
Relmada Therapeutics, Inc. (RLMD) P/E ratio
Relmada Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 375× (April 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 375×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RLMD Relmada Therapeutics, Inc. | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | n/m |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)